• Researcher Profile

    Rebecca S. Gelman, PhD

    Rebecca S. Gelman, PhD
    Associate Professor of Medicine, Harvard Medical School
    Associate Professor of Biostatistics, Harvard T.H. Chan School of Public Health

    Office phone: 617-632-3629
    Fax: 617-632-2444
    Email: gelman@jimmy.harvard.edu

    Preferred contact method: email

    Research Department

    Biostatistics and Computational Biology

    Area of Research

    Biostatistics in Clinical Cancer Studies and AIDS Research

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    CLSB 11156
    Boston, MA 02215


    Dr. Gelman received her PhD in statistics from the State University of New York, Buffalo, in 1978. In the same year, she joined the Department of Biostatistics at Harvard School of Public Health and DFCI, and in 1990, the Department of Radiation Oncology at Harvard Medical School. She is associate director of the Biostatistics Core of the Dana-Farber/Harvard Cancer Center, principal investigator of the Biostatistics Core of the Harvard Center for AIDS Research, and chief statistician for the National Institute of Allergy and Infectious Diseases (NIAID) Division of AIDS Immunology Laboratory Quality Assessment Program. She is the only statistician member of the Flow Advisory Committee to the NIAID.


    Biostatistics in Clinical Cancer Studies and AIDS Research

    Our research involves two main areas: collaboration on cancer and HIV studies and the statistical problems arising from them. Our work is focused primarily on studies of breast cancer (both laboratory and clinical), radiation oncology, immunology, and evaluation of new immunology assays, particularly those involving flow cytometry.

    Recent research activities in cancer include (1) modeling the effects of screening and therapy on breast cancer mortality in the United States (with the NIH CISNET group), (2) designing xenograft growth experiments to assess the cancer-promotion abilities of various stromal and fibroblast cells, (3) assessing longitudinal circulating tumor markers in breast cancer, (4) designing breast cancer prevention pilot studies, and (5) analyzing long-term follow-up on several randomized breast cancer therapy trials.

    Recent research activities in HIV disease include (1) modeling changes in the distributions of percents and counts of various lymphocyte subsets in healthy children from birth to age 18 (for use as controls in pediatric HIV and cancer studies), (2) quantitating the co-localization of CD8 cells and JC virus (JCV)-infected glial cells in brain biopsies from patients with progressive multifocal leukoencephalopathy (PML) disease, (3) analyzing the effect of various immune maneuvers on the effectiveness of vaccines against simian-human immunodeficiency viruses (SHIV), and (4) designing and analyzing studies that compare the within-laboratory and between-laboratory variability in CD4 counts using either current methods or several cheaper and simpler methods being developed for use in the third world.

    Our statistical interests include methods (1) to analyze nonindependent competing risks, (2) to assess the surrogate value of longitudinal markers in cancer and HIV disease (particularly methods that incorporate external information on within-laboratory and between-laboratory variation in assessing these markers), and (3) to assess the heterogeneity of distributions of various types of cells in pathology specimens or high-definition imaging techniques.

View Physician Directory

Find a Clinical Trial

Support Cancer

Give Now